Vir hepatitis D drug succeeds in first pivotal study
BioPharma DiveDelilah AlvaradoNovember 9, 2026
A program that s survived Vir s pivot away from infectious disease research hit all of its study objectives and appeared more potent than a rival drug also in late-stage development.